Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors
- 10 February 2007
- journal article
- phase i-and-clinical-pharmacology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (5) , 540-547
- https://doi.org/10.1200/jco.2006.07.8097
Abstract
Purpose Based on prostate-specific membrane antigen (PSMA) expression on the vasculature of solid tumors, we performed a phase I trial of antibody J591, targeting the extracellular domain of PSMA, ...Keywords
This publication has 12 references indexed in Scilit:
- Targeted therapy in renal cell carcinomaExpert Opinion on Investigational Drugs, 2005
- Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2005
- High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Journal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Vascular Targeting Agents as Cancer TherapeuticsClinical Cancer Research, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Genes Expressed in Human Tumor EndotheliumScience, 2000
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995
- Reporting results of cancer treatmentCancer, 1981